论文部分内容阅读
目的 :探讨急性髓细胞白血病 ( AML)的免疫表型特点。方法 :使用淋系和髓系单抗 ,用间接免疫荧光法对 70例原发性 AML 进行免疫表型分析。结果 :所有 AML 患者的细胞至少被 1种髓系单抗标记 ,各髓系抗原的表达率依次为 CD3 3 >CD1 3 >CD1 5 。所有 M3 患者 CD9为阳性。 16 /70例 ( 30 % )表达 CD3 4 抗原、CD+3 4 AML 组在年龄、外周血象及骨髓原始、幼稚细胞比例等方面与 CD- 3 4 组相比较无显著差别 ,但表达 CD3 4 抗原的 AML常伴有HL A - DR、CD3 8、CD7等不成熟细胞表面标记的表达 ,而较成熟的髓系细胞表面标记 CD1 5 则不表达。 70例 AML中有 16例表达淋系抗原 ,CD+4 6例 ( 13.8% ,M2 为 8.8% ,M46 0 % ) ;CD+79例 ( 16 .9% ,M1 为 5 0 % ,M2 18% ,M5 b16 .7% )。CD+4 的 AML 患者 CD3 4 为低表达 ,CD3 3 高表达。结论 :CD+9、CD- 3 4 、HL A- DR-及 CD+1 3 和 /或 CD+3 3 、CD+1 5 是典型M3 的免疫表型特点。CD+3 4 AML与 AML - M1 有着密切的关系 ,且对化疗反应较差 ,证明 CD+3 4 的 AML是一组分化程度较差的类型 ;提示 CD+7和 CD+4 的 AML 预后差 ,CD+7的 AML 是 AML 的一种独特类型
Objective: To investigate the immunophenotypic characteristics of acute myeloid leukemia (AML). Methods: Immunohistochemical analysis of 70 cases of primary AML was performed by indirect immunofluorescence using lymphoid and myeloid monoclonal antibodies. Results: All AML patients were labeled with at least one myeloid monoclonal antibody. The expression rates of all myeloid antigens were CD3 3> CD1 3> CD1 5. CD9 was positive in all M3 patients. There was no significant difference between CD34 group and CD34 group in 16 of 70 cases (30%), and CD34 + antigen of CD34 + AML group in age, peripheral blood, bone marrow and naive cells Of AML is often accompanied by the expression of immature cell surface markers such as HL A - DR, CD3 8 and CD7, while the mature myeloid cell surface marker CD1 5 is not expressed. Sixteen of 70 AML cases expressed lymphoid antigens, with CD + 4 (13.8%, M2 8.8%, M46 0%); CD 79 cases (16.9%, M1 50%, M2 18% , M5 b16 .7%). CD3 4 in CD + 4 AML patients was low and CD3 3 was highly expressed. Conclusion: CD + 9, CD- 34, HL A- DR- and CD + 13 and / or CD + 3 3 and CD + 15 are the immunophenotypic features of typical M3. CD + 3 4 AML is closely related to AML - M1 and has a poor response to chemotherapy, demonstrating that CD + 34 AML is a poorly differentiated group; suggesting a poor prognosis for AML with CD + 7 and CD + 4 AML for CD + 7 is a unique type of AML